Stocks Health care ATRA
NASDAQ · Health careAtara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. brought in $6.2M of revenue over the twelve months to June 30, 2026, down 96.7% from a year earlier. It posted a net loss of $16.7M. In fiscal 2025 capital spending exceeded operating cash flow by $50.9M. At June 30, 2026 it held $3.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Atara Biotherapeutics, Inc.
- Net worth
- Atara Biotherapeutics, Inc. has a market value (market cap) of $82.1M at the latest share price, and shareholders' equity of -$37M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $120.8M (-6.3% year on year), with net income of $32.7M. Over the 12 months to June 30, 2026: revenue $6.2M, net loss $16.7M.
- Cash flow
- In fiscal 2025 operations used $50.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Atara Biotherapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Atara Biotherapeutics, Inc. does
Atara Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ATRA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $120.8M | $32.7M | $2.57 | -$50.9M |
| 2024 | $128.9M | -$85.4M | -$11.41 | -$69M |
| 2023 | $8.6M | -$276.1M | -$65.19 | -$194.2M |
| 2022 | $63.6M | -$228.3M | -$55.95 | -$274.6M |
| 2021 | n/a | -$340.1M | -$90.67 | -$231.1M |
| 2020 | n/a | -$306.6M | -$103.65 | -$185.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ATRA ranks in Health care
Latest SEC filings
What Atara Biotherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 96% to $630K versus the same quarter last year; diluted EPS -$0.32 versus $0.19.
- August 12, 2026
- July 24, 2026Activist stake changed SCHEDULE 13D/A
- June 26, 2026
- June 12, 2026
- June 12, 2026
- May 14, 2026Activist stake changed SCHEDULE 13D/A
- May 13, 2026Passive stake (5% or more) SCHEDULE 13G
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 99% to $516K versus the same quarter last year; diluted EPS -$0.29 versus $3.50.
Insider trades
What the people running Atara Biotherapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $1M and sold $40.9K worth of shares in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 4, 2026 | Cherry Brian NDirector | Bought | 104,166 | $1M |
| August 17, 2026 | Nguyen AnhCoPresident and CEO, Director | Sold | 5,062 | $40.9K |
| July 22, 2026 | Redmile Group, LLCDirector | Exercised optionsindirect | 195,211 | - |
| July 22, 2026 | Redmile Group, LLCDirector | Shares withheld for taxindirect | 60 | - |
| June 11, 2026 | Cherry Brian NDirector | Received as pay | 24,000 | - |
| June 9, 2026 | Ciongoli Gregory AustinDirector, 10% owner | Received as pay | 12,000 | - |
| June 9, 2026 | Fust Matthew KDirector | Received as pay | 12,000 | - |
| June 9, 2026 | Heiden William KDirector | Received as pay | 12,000 | - |
Who owns ATRA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Adiumentum Capital Fund I LP13D, may seek influence with 2 related filers | 19.99% | May 16, 2025 |
| EcoR1 Capital, LLC13G, passive with 2 related filers | 17.4% | May 7, 2026 |
| Panacea Innovation Limited13D, may seek influence with 5 related filers | 16.1% | May 11, 2026 |
| Redmile Group, LLC13D, may seek influence with 3 related filers | 9.9% | July 24, 2026 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 8.56% | May 13, 2026 |
| Point72 Asset Management, L.P.13G, passive with 2 related filers | 7.6% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 36 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| EcoR1 Capital, LLC | 1,552,000 | +1,452,407 |
| Adage Capital Partners GP, L.L.C. | 850,000 | +150,000 |
| Point72 Asset Management, L.P. | 687,718 | +493,454 |
| Redmile Group, LLC | 441,701 | 0 |
| Vanguard Capital Management LLC | 247,047 | +29,185 |
| Mackenzie Financial Corp | 233,249 | -80,371 |
| BlackRock, Inc. | 84,455 | +5,433 |
| Geode Capital Management, LLC | 75,128 | +8,982 |
| Staley Capital Advisers Inc | 50,000 | 0 |
| Vanguard Fiduciary Trust Co | 43,036 | +9,415 |
| Jane Street Group, LLC | 30,345 | -3,525 |
| State Street Corp | 26,453 | 0 |
| Northern Trust Corp | 16,591 | +4,251 |
| Fmr LLC | 16,238 | 0 |
| XTX Topco Ltd | 15,303 | new |
| Bridgeway Capital Management, LLC | 14,000 | -18,691 |
| Millennium Management LLC | 12,680 | -35,009 |
| Citadel Advisors LLC | 10,159 | new |
| Morgan Stanley | 9,178 | +9 |
| Royal Bank of Canada | 4,743 | +424 |
Insiders
9 insiders reported holding 3,625,125 shares in total, about $29.7M at the last price.
| Holder | Shares |
|---|---|
| EcoR1 Capital, LLC10% owner | 1,552,0001,552,000 held indirectly |
| Panacea Innovation LtdDirector, 10% owner | 1,011,0001,011,000 held indirectly |
| Redmile Group, LLCDirector | 636,852636,852 held indirectly |
| Cherry Brian NDirector | 166,486 |
| Nguyen AnhCoPresident and CEO, Director | 132,775 |
| Grant-Huerta YaninaChief Accounting Officer | 49,636 |
| Heiden William KDirector | 34,188 |
| Fust Matthew KDirector | 30,188 |
| Ciongoli Gregory AustinDirector, 10% owner | 12,000 |
Questions about ATRA
What does Atara Biotherapeutics, Inc. do?
Atara Biotherapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ATRA. Its shares trade on NASDAQ under the ticker ATRA.
What is Atara Biotherapeutics, Inc.'s net worth?
Atara Biotherapeutics, Inc. has a market value (market cap) of $82.1M at the latest share price, and shareholders' equity of -$37M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Atara Biotherapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $16.7M on revenue of $6.2M.
How much revenue does Atara Biotherapeutics, Inc. make?
Over the twelve months to June 30, 2026 Atara Biotherapeutics, Inc. reported revenue of $6.2M. That is 96.7% less than a year earlier.
When did Atara Biotherapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 4, 2026.
When is Atara Biotherapeutics, Inc.'s next earnings report?
Atara Biotherapeutics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ATRA with
Follow ATRA
Get an email when Atara Biotherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Atara Biotherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.